NSE:HDFCAMC

HDFC Asset Management Assigned ESG Rating of 74 by NSE Sustainability

HDFC Asset Management (NSE:HDFCAMC, BOM:541729) said NSE Sustainability Ratings and Analytics has assigned the company an ESG rating of 74.

Jefferies Adjusts HDFC Asset Management's Price Target to INR3,130 From INR3,090, Keeps at Buy

HDFC Asset Management (NSE:HDFCAMC, BOM:541729) has an average rating of overweight and mean price target of 3,064.48 Indian rupees, according to analysts polled by FactSet.

Nomura Adjusts HDFC Asset Management's Price Target to INR3,130 From INR2,950, Keeps at Buy

HDFC Asset Management (NSE:HDFCAMC, BOM:541729) has an average rating of buy and mean price target of 3,018.52 Indian rupees, according to analysts polled by FactSet.

Jefferies Adjusts HDFC Asset Management's Price Target to INR3,090 from INR2,960, Keeps at Buy

HDFC Asset Management (NSE:HDFCAMC, BOM:541729) has an average rating of buy and mean price target of 2,980.85 Indian rupees, according to analysts polled by FactSet.

Indian Equities Slip on Thursday Amid Profit Booking in Heavyweights

Indian benchmark indices closed marginally lower on Thursday as profit booking in select large stocks offset early optimism.The BSE Sensex slipped 122.56 points, or 0.2%, to finish at 77,988.68, while the NSE Nifty 50 fell 34.55 points, or 0.1%, to close at 24,196.75.Sentiment remained mildly supported by expectations of a second round of US-Iran talks aimed at easing the ongoing conflict. Uncertainty over timing, however, kept investors cautious.On the macro side, India's Wholesale Price Index (WPI) inflation rose to 3.88% in March, up from 2.13% in February, according to government data released late on Wednesday. Goods and services exports also declined 4.58% year-on-year to $74.11 billion in March.Among stocks, HDFC Asset Management Company (NSE:HDFCAMC, BOM:541729) reported a slight dip in consolidated profit to 6.23 billion rupees in Q4 FY26 from 6.38 billion rupees a year earlier. Revenue from operations rose to 10.5 billion rupees from 9.01 billion rupees, according to its filing.Alembic Pharmaceuticals (NSE:APLLTD, BOM:533573) gained after receiving US FDA approval for Methotrexate Injection in both multi-dose and single-dose vials. The drug is used in cancer treatment as well as autoimmune conditions including rheumatoid arthritis and psoriasis.

HDFC Asset Management's Consolidated Profit Declines in Fiscal Q4

HDFC Asset Management Company's (NSE:HDFCAMC, BOM:541729) consolidated attributable profit declined to 6.23 billion Indian rupees in the fiscal fourth quarter ended March 31, from 6.38 billion rupees a year ago.Earnings per share contracted to 14.48 rupees from 14.89 rupees a year earlier, the asset management company said in a filing to the Indian stock exchanges on Thursday.Revenue from operations in fiscal Q4 rose to 10.5 billion rupees from 9.01 billion rupees a year ago.The company's board recommended a final dividend of 54 rupees per equity share of 5 rupees each of the company, for the financial year ended March 31.The company's shares were down over 1% in recent trade.

Emkay Global Starts HDFC Asset Management at Buy with INR3,200 Price Target

JM Financial Upgrades HDFC Asset Management to Buy from Add; Price Target is INR3,200